| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5959364 | Heart Rhythm | 2016 | 29 Pages |
Abstract
ATP was effective in terminating VT/FVT episodes and displayed a good safety profile. ATP therapies by themselves did not increase death risk; prognosis was indeed better in patients without arrhythmic episodes, even if they received inappropriate ATP, than in patients with ATP on VT/FVT episodes. Adverse outcomes observed in patients receiving implantable cardioverter-defibrillator therapies are probably related to the arrhythmia itself, a marker of disease progression, rather than to adverse effects of ATP.
Keywords
FVTCRT-Dantitachycardia pacingCardiac resynchronization therapy defibrillatorATPSafetyVentricular tachycardiaGEEICDimplantable cardioverter-defibrillatorsconfidence intervalVentricular fibrillationAtrial fibrillationDeathgeneralized estimating equationheart failurehazard ratioImplantable cardioverter-defibrillator
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Maurizio MD, Maurizio MD, Giuseppe MD, Renato MD, Alessandro MD, Domenico MD, Roberto MD, Giovanni MD, Massimiliano MD, Gianni MD, Giulio MD, Pietro MD, Maurizio MD,